EBITDA: Income before interest, taxes, depreciation and amortization.
Spyre Therapeutics, Inc. (SYRE) had EBITDA of $-57.17M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-62.53M |
|
-- |
|
-- |
|
$57.17M |
|
$-57.17M |
|
$-5.36M |
|
$-62.53M |
|
$-62.53M |
|
$-62.53M |
|
$-62.53M |
|
$-62.53M |
|
$-62.53M |
|
$-57.17M |
|
|
EBITDA |
$-57.17M |
64.06M |
|
64.06M |
|
$-1.18 |
|
$-1.18 |
|
| Balance Sheet Financials | |
$777.78M |
|
-- |
|
-- |
|
$777.78M |
|
$58.69M |
|
-- |
|
$3.86M |
|
$62.55M |
|
$559.42M |
|
$715.24M |
|
$715.24M |
|
78.19M |
|
| Cash Flow Statement Financials | |
$-169.25M |
|
$-143.47M |
|
$309.02M |
|
$89.42M |
|
$85.72M |
|
$-3.70M |
|
$37.61M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.25 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-169.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.18% |
|
-8.74% |
|
-8.04% |
|
-8.74% |
|
$9.15 |
|
$-2.64 |
|
$-2.64 |
|